The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.
 
Margherita Rimini
No Relationships to Disclose
 
Andrea Casadei-Gardini
No Relationships to Disclose
 
Mara Persano
No Relationships to Disclose
 
Toshifumi Tada
No Relationships to Disclose
 
Goki Suda
No Relationships to Disclose
 
Shigeo Shimose
No Relationships to Disclose
 
Masatoshi Kudo
Honoraria - Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Research Funding - Abbvie (Inst); Chugai/Roche; EA Pharma (Inst); Eisai (Inst); GE Healthcare; Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Jaekyung Cheon
No Relationships to Disclose
 
Fabian Finkelmeier
No Relationships to Disclose
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Eisai; Gilead Sciences; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; ArQule; AstraZeneca; Basilea; Baxter; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Exelixis; Genenta Science; Hengrui Therapeutics; Incyte; Ipsen; IQvia; Italfarmaco; Lilly; Merck Sharp & Dohme; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Oncology; Zymeworks
Research Funding - Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nerviano Medical Sciences (Inst); Roche; Zymeworks (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Ipsen
 
Josè Presa
No Relationships to Disclose
 
Gianluca Masi
Consulting or Advisory Role - AstraZeneca; Eisai; MSD Oncology
Patents, Royalties, Other Intellectual Property - Terumo (Inst)
 
Changhoon Yoo
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; MSD Oncology; SERVIER
Speakers' Bureau - Bayer; Celgene; Eisai; Ipsen; Merck Sharp & Dohme; Novartis
Research Funding - AstraZeneca; Bayer; CKD pharm; SERVIER
 
Sara Lonardi
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Lilly; Merck Serono; Mirati Therapeutics; MSD; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Francesco Tovoli
No Relationships to Disclose
 
Mario Scartozzi
No Relationships to Disclose
 
Valentina Burgio
No Relationships to Disclose
 
Stefano Cascinu
Honoraria - BMS; Lilly; MSD Oncology; Sanofi; Servier
Consulting or Advisory Role - BMS; Lilly; MSD Oncology; SERVIER
Speakers' Bureau - Lilly; SERVIER
Travel, Accommodations, Expenses - Bayer; Celgene; Lilly
 
Alessandro Cucchetti
No Relationships to Disclose